chr17-79106754-G-A
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_001350451.2(RBFOX3):c.257C>T(p.Pro86Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000413 in 1,524,860 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 11/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_001350451.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RBFOX3 | NM_001350451.2 | c.257C>T | p.Pro86Leu | missense_variant | 6/15 | ENST00000693108.1 | NP_001337380.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RBFOX3 | ENST00000693108.1 | c.257C>T | p.Pro86Leu | missense_variant | 6/15 | NM_001350451.2 | ENSP00000510395 |
Frequencies
GnomAD3 genomes AF: 0.0000657 AC: 10AN: 152178Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000628 AC: 8AN: 127476Hom.: 0 AF XY: 0.0000876 AC XY: 6AN XY: 68480
GnomAD4 exome AF: 0.0000386 AC: 53AN: 1372682Hom.: 0 Cov.: 31 AF XY: 0.0000502 AC XY: 34AN XY: 676908
GnomAD4 genome AF: 0.0000657 AC: 10AN: 152178Hom.: 0 Cov.: 33 AF XY: 0.0000807 AC XY: 6AN XY: 74332
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 17, 2023 | The c.257C>T (p.P86L) alteration is located in exon 5 (coding exon 2) of the RBFOX3 gene. This alteration results from a C to T substitution at nucleotide position 257, causing the proline (P) at amino acid position 86 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Idiopathic generalized epilepsy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 09, 2023 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RBFOX3 protein function. This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 86 of the RBFOX3 protein (p.Pro86Leu). This variant is present in population databases (rs377660420, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with RBFOX3-related conditions. ClinVar contains an entry for this variant (Variation ID: 411177). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at